Patent application number | Description | Published |
20090054516 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME - A pharmaceutical composition having a cytotoxic effect to a cancer cell and a method for the same are provided. The pharmaceutical composition comprises a flavonoid compound having at least one of the following formulas: | 02-26-2009 |
20090088412 | COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD THEREOF - A composition for treating cancer cells and a preparation method therefore is provided. The composition includes novel withanolide compounds derived from a Solanaceae plant, which the novel withanolide compounds have the cytotoxicity to the cancer cells. | 04-02-2009 |
20090221696 | COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD FOR THE SAME - A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells. | 09-03-2009 |
20100056812 | COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD FOR THE SAME - A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells. | 03-04-2010 |
20100062078 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND THE SIGNALING PATHWAY THEREOF - A pharmaceutical composition, composed of protoapigenone (formula I), for treating gynecological cancers, prostate cancer, urinary bladder cancer and hepatocarcinoma is provided. Protoapigenone has cytotoxicity on these cancers, and arrests the cell cycle at S and G2/M phases. In addition, protoapigenone regulates cell signaling pathways, such as caspase-3, PARP, p-38 MAPK and JNK½, to induce apoptosis. Protoapigenone significantly inhibits the xenograft tumor growth on nude mice, without major side effects. Co-treatment o protoapigenone of protoapigenone and cisplatin shows synergistic cytotoxicity of MDAH-2774 ovarian cancer cells. | 03-11-2010 |
20100081832 | COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD FOR THE SAME - A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells. | 04-01-2010 |
20100210869 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF - A preparation method for an ethanol extract of the fruiting body of | 08-19-2010 |
20100227404 | WATER EXTRACT OF ANTRODIA CAMPHORATA FOR IMMUNOSTIMULATORY EFFECT AND PREPARATION METHOD THEREOF - A preparation method for a water extract of the fruiting body of | 09-09-2010 |
20110159127 | EXTRACT OF TOONA SINENSIS FROM SUPERCRITICAL FLUID EXTRACTION FOR TREATING DIABETES AND METABOLIC DISEASES, THE PREPARATION METHOD AND THE USE THEREOF | 06-30-2011 |
20110196029 | COMPOSITION FOR TREATING INFLUENZA A (H1N1) VIRUS AND A PREPARATION METHOD THEREFOR - New pharmaceutical compositions extracted from | 08-11-2011 |
20120141524 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF - A preparation method for an ethanol extract of the fruiting body of | 06-07-2012 |
20120178945 | BENZENOID COMPOUNDS OF ANTRODIA CINNAMOMEA, PREPARATION AND ANALYSIS METHOD THEREOF - Disclosed are a method for preparing an n-hexane extract of the fruiting body of | 07-12-2012 |
20120190871 | TRITERPENOID COMPOSITION OF ANTRODIA CINNAMOMEA, PREPARATION AND ANALYSIS METHOD THEREOF - Disclosed are the isolation, purification and analysis of the triterpenoid compositions (including ergostane and lanostane) in the fruiting body of | 07-26-2012 |
20120321566 | INHIBITION OF BIOFILM FORMATION BY 1,2,3,4,6-PENTA-O-GALLOYL-D-GLUCOPYRANOSE - Disclosed herein are an anti-biofilm composition and a method to inhibit or prevent cell adhesion and/or biofilm formation by a microorganism, in which use of 1,2,3,4,6-penta-O-galloyl-D-glucopyranose (PGG) is involved therein. | 12-20-2012 |
20130000389 | CHEMICAL PROFILE OF DETECTING BIOACTIVE COMPONENTS OF QUINONES, STILBENES, FLAVONES AND ALKALOIDS - Disclosed are a method for analyzing chemical profiles of components from a herbal medicine product. Components may include quinone (including rhein, sennoside A and/or aloe-emodin), stilbene containing resveratroloside, flavone including baicalin, and/or alkaloid including berberine and/or palmatine. The method includes steps of: (a) respectively chromatographing a methanol extract of product and standard(s) corresponding to the component(s) using HPLC; (b) comparing HPLC chromatogram of extract and standard(s); and (c) analyzing the chemical profiles of the product from the comparison results. | 01-03-2013 |
20130040996 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF - Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL). | 02-14-2013 |
20130245114 | COMPOSITION FOR TREATING INFLUENZA A (H1N1) VIRUS AND A PREPARATION METHOD THEREFOR - New pharmaceutical compositions extracted from | 09-19-2013 |
20140194474 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF - Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL). | 07-10-2014 |
20140221470 | COMPOUND FOR INHIBITING GLUTATHIONE S-TRANSFERASE OMEGA 1 ACTIVITY, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, AND METHOD FOR SYNTHESIZING THE SAME - A compound for inhibiting activity of glutathione s-transferase omega 1 is provided and is represented by the following Formula 1: | 08-07-2014 |
20140350304 | COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF - Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed. | 11-27-2014 |